Clinical Trial

Testing Experimental Treatment for Psoriatic Arthritis

Study Description

A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis

This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable Methotrexate (MTX), on Magnetic resonance imaging (MRI) outcomes in subjects with active PsA with up to 5 years of disease duration (since diagnosis).

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - CC-10004

CC-10004

Additional Information

Official Study Title

A PHASE 4, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST (CC-10004) MONOTHERAPY ON MRI OUTCOMES IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

Clinical Trial ID

NCT03783026

ParticipAid ID

dG6Qyb